[1] |
Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group.
Expert consensus on the treatment of tuberculosis with contezolid
[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129.
|
[2] |
Wang Xueyu, Wang Yujin, Chu Naihui, Kang Wanli, Nie Wenjuan.
A preliminary study on the enhanced in vivo exposure of sudapyridine in Mycobacterium abscessus-infected rats with the co-administration of clofazimine or clarithromycin
[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 150-157.
|
[3] |
Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan.
Safety of extended delamanid use in drug-resistant tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
|
[4] |
Shi Lulu, Jing Hui, Liang Min, Li Xuezheng.
Analysis of clinical results of blood concentration detection of antituberculosis drugs by liquid chromatography-tandem mass spectrometry
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 886-891.
|
[5] |
Duan Shujuan, Wang Wei, Pang Yu, Li Ling.
Research progress on the regulation of host anti-tuberculosis effect by tyrosine kinase inhibitors
[J]. Chinese Journal of Antituberculosis, 2024, 46(5): 584-589.
|
[6] |
Jiayinati Jingesi, Wang Xinqi, Liu Nianqiang, Wang Senlu, Yipaer Aihaiti, Feng Jianyu, Huang Tao, Kedieryekezi Wufuer.
Analysis of treatment completeness and its influencing factors of preventive treatment among 387 latent tuberculosis infection cases
[J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1496-1503.
|
[7] |
Shi Chunjing, Liu Xing, Li Longfen, Li Wenming, Zhang Huajie, Wang Ge, Zeng Haiyan, Liu Li, Shen Lingjun.
Research progress on the effects of bedaquiline,delamanid and pretomanid on liver function in the treatment of multidrug-resistant tuberculosis
[J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1560-1565.
|
[8] |
Sha Wei.
Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control
[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192.
|
[9] |
Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University.
Expert consensus on clinical monitoring and management of QTc interval prolongation caused by anti-tuberculous drugs
[J]. Chinese Journal of Antituberculosis, 2024, 46(1): 8-17.
|
[10] |
Peng Jiangli, Chen Jie, Chen Yonggang, Wang Lu, Li Na, Luo Ji, Han Yi, Yu Mingli, Zhu Jiangchun.
SLC22A12 gene polymorphism study on susceptibility to hyperuricemia induced by pyrazinamide
[J]. Chinese Journal of Antituberculosis, 2023, 45(2): 151-158.
|
[11] |
Wang Honghong, Guo Shaochen, Zhou Wenqiang, Liu Zhongquan, Zhu Hui, Lu Yu.
Influence of linezolid blood concentration on hematological toxicity in drug-resistant tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2023, 45(2): 165-171.
|
[12] |
Chen Fang, Zhang Xiaofo, Zhou Haiyi, Zhang Feng, Wang Manzhi.
Analysis of status and influencing factors associated with anti-tuberculosis drug-related liver injury in children
[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 45-51.
|
[13] |
LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu.
A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653.
|
[14] |
LU Ni-hong, SHEN Ling-jun, LIU Hong-lu, CHEN Yang-jun, YANG Yan, DU Ying-rong.
Clinical value of ESAT-6, immune and inflammatory indexes in the diagnosis of anti-tuberculosis drug-induced liver injury
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 654-659.
|
[15] |
NIE Wen-juan, ZHOU Wen-qiang, CHU Nai-hui.
Research progress on pharmacokinetics and drug interaction of bedaquiline
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 716-719.
|